No differences in body composition were found among metastatic castration-resistant prostate cancer patients taking abiraterone acetate (ZYTIGA), enzalutamide (Xtandi), or placebo who were treated as part of two clinical trials.
Outcomes following salvage radiation therapy after recurrent prostate cancer in a racially mixed cohort are no better when it’s started at a PSA level
Regular use of aspirin in the year before a diagnosis of stage I-III prostate cancer is associated with a reduction in prostate cancer-specific mortality, say Irish researchers.
A personalized immunotherapy (AGS-003) nearly doubled expected progression-free survival and overall survival when added to standard sunitinib (Sutent) in patients with unfavorable-risk metastatic renal cell carcinoma, according to results from a single-arm phase II study.
Older men with metastatic castration-resistant prostate cancer (CRPC) derive a similar if not superior survival benefit from treatment with enzalutamide (Xtandi) as do younger men, according to a post-hoc analysis of the phase III AFFIRM trial.
Use of tivozanib, an experimental tyrosine kinase inhibitor (TKI) with increased specificity and potency for the vascular endothelial growth factor (VEGF) receptor, as initial targeted therapy for patients with advanced renal cell carcinoma did not translate into improved overall survival compared with sorafenib (Nexavar) in a phase III clinical trial.
Advanced age does not influence postoperative continence or cancer-specific survival after radical prostatectomy, according to a recent study.
Intradetrusor injections of onabotulinumtoxinA (Botox) do not significantly reduce urinary frequency in patients with refractory overactive bladder secondary to BPH, results from a two-institution, placebo-controlled study indicate.
In patients with stage pT1 urothelial bladder cancer, intravesical bacillus Calmette-Guérin (TheraCys, TICE BCG) combined with electromotive mitomycin-C produces higher remission rates and longer remission times than BCG alone, Italian researchers reported.
In the hands of high-volume surgeons, there is no evidence to suggest that robot-assisted laparoscopic prostatectomy results in worse oncologic outcomes then open radical prostatectomy, even in patients with high-risk cancer.